Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma

References

• Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25. doi:10.1007/s00261-017-1209-1
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. Reply. N Engl J Med. 2019;381(1):e2. doi:10.1056/NEJMc1906565
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-430061739
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 19902017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-131248666
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–761. doi:10.1053/j.gastro.2016.11.04828043904
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(8):436. doi:10.1038/nrclinonc.2015.121
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183. doi:10.1016/j.j.hep.2017.03.00728323121
   PubMed Web of Science ®Google Scholar
• Ikeda M, Morizane C, Ueno M, et al. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103–114. doi:10.1093/jjco/hyx18029253194
   PubMed Web of Science ®Google Scholar
• Ikeda M, Mitsunaga S, Ohno I, et al. Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future. Diseases. 2015;3(4):360–381. doi:10.3390/diseases304036028943630
   PubMedGoogle Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Haris M, Yadav SK, Rizwan A, et al. Molecular magnetic resonance imaging in cancer. J Transl Med. 2015. 13:313. doi:10.1186/s12967-015-0659-x
   Web of Science ®Google Scholar
• Hasegawa S, Furukawa T, Saga T. Molecular MR imaging of cancer gene therapy: ferritin transgene reporter takes the stage. Magn Reson Med Sci. 2010;9(2):37–47. doi:10.2463/mrms.9.3720585193
   PubMed Web of Science ®Google Scholar
• Zhang F, Duan X, Lu L, et al. In vivo long-term tracking of neural stem cells transplanted into an acute ischemic stroke model with reporter gene-based bimodal MR and optical imaging. Cell Transplant. 2017;26(10):1648–1662. doi:10.1177/096368971772256029251112
   PubMed Web of Science ®Google Scholar
• Kim KI, Chung HK, Park JH, et al. Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma. World J Gastroenterol. 2016;22(27):6127–6134. doi:10.3748/wjg.v22.i27.612727468205
   PubMed Web of Science ®Google Scholar
• Park JH, Kim KI, Lee KC, et al. Assessment of α-fetoprotein targeted HSV1-tk expression in hepatocellular carcinoma with in vivo imaging. Cancer Biother Radiopharm. 2015;30(1):8–15. doi:10.1089/cbr.2014.171625545853
   PubMed Web of Science ®Google Scholar
• Ramalho J, Ramalho M. Gadolinium deposition and chronic toxicity. Magn Reson Imaging Clin N Am. 2017;25(4):765–778. doi:10.1016/j.mric.2017.06.00728964466
   PubMed Web of Science ®Google Scholar
• Layne KA, Dargan PI, Archer J, et al. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol. 2018;84(11):2522–2534. doi:10.1111/bcp.1371830032482
   PubMed Web of Science ®Google Scholar
• Cao M, Mao J, Duan X, et al. In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. Int J Cancer. 2018;142(5):1033–1046. doi:10.1002/ijc.3111329047121
   PubMed Web of Science ®Google Scholar
• Yang C, Tian R, Liu T, et al. MRI reporter genes for noninvasive molecular imaging. Molecules. 2016;21(5). doi:10.3390/molecules21050580
   Web of Science ®Google Scholar
• Yang Y, Gong MF, Yang H, et al. MR molecular imaging of tumours using ferritin heavy chain reporter gene expression mediated by the hTERT promoter. Eur Radiol. 2016;26(11):4089–4097. doi:10.1007/s00330-016-4259-926960542
   PubMed Web of Science ®Google Scholar
• Ono K, Fuma K, Tabata K, et al. Ferritin reporter used for gene expression imaging by magnetic resonance. Biochem Biophys Res Commun. 2009;388(3):589–594. doi:10.1016/j.bbrc.2009.08.05519683514
   PubMed Web of Science ®Google Scholar
• Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. JACC Cardiovasc Imaging. 2011;4(7):799–806. doi:10.1016/j.jcmg.2011.05.00321757172
   PubMed Web of Science ®Google Scholar
• Cohen B, Dafni H, Meir G, et al. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005;7(2):109–117. doi:10.1593/neo.0443615802016
   PubMed Web of Science ®Google Scholar
• Hongliang H, et al. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-g-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector[M]. Biomaterials. 2010. doi:10.1016/j.biomaterials.2009.11.012
   Web of Science ®Google Scholar
• Kim KI, Lee YJ, Lee TS, et al. In vitro radionuclide therapy and in vivo scintigraphic imaging of alpha-fetoprotein-producing hepatocellular carcinoma by targeted sodium iodide symporter gene expression. Nucl Med Mol Imaging. 2013;47(1):1–8. doi:10.1007/s13139-012-0166-424895502
   PubMedGoogle Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118. doi:10.1053/j.gastro.2009.04.00519362088
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Luther E, Torchilin V. The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells. J Drug Target. 2019;27(56):601–613. doi:10.1080/1061186X.2018.155064730475084
   PubMedGoogle Scholar
• Moghimipour E, Rezaei M, Kouchak M, et al. A mechanistic study of the effect of transferrin conjugation on cytotoxicity of targeted liposomes. J Microencapsul. 2018;35(6):548–558. doi:10.1080/02652048.2018.154732530445885
   PubMed Web of Science ®Google Scholar
• Bao W, Liu R, Wang Y, et al. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int J Nanomed. 2015;10:557–566. doi:10.2147/IJN.S75090
   PubMed Web of Science ®Google Scholar
• Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005;10(4):267–273. doi:10.1016/S1359-6446(04)03333-115708745
   PubMed Web of Science ®Google Scholar
• Bigdeli A, Palchetti S, Pozzi D, et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano. 2016;10(3):3723–3737. doi:10.1021/acsnano.6b0026126882007
   PubMed Web of Science ®Google Scholar
• Panahi Y, Farshbaf M, Mohammadhosseini M, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif Cells Nanomed Biotechnol. 2017;45(4):788–799. doi:10.1080/21691401.2017.128249628278586
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267–3285. doi:10.2174/09298670978880331219548866
   PubMed Web of Science ®Google Scholar
• Szwed M, Wrona D, Kania KD, et al. Doxorubicin-transferrin conjugate triggers pro-oxidative disorders in solid tumor cells. Toxicol in Vitro. 2016;31:60–71. doi:10.1016/j.tiv.2015.11.00926607004
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–1225. doi:10.1016/j.yjmcc.2012.03.00622465037
   PubMed Web of Science ®Google Scholar
• Carvalho FS, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106–135. doi:10.1002/med.2128023494977
   PubMed Web of Science ®Google Scholar
• Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anticancer Drugs. 2015;26(3):241–258. doi:10.1097/CAD.000000000000018225415656
   PubMed Web of Science ®Google Scholar
• Anabousi S, Laue M, Lehr CM, et al. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm. 2005;60(2):295–303. doi:10.1016/j.ejpb.2004.12.00915939240
   PubMed Web of Science ®Google Scholar
• Li X, Ding L, Xu Y, et al. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm. 2009;373(12):116–123. doi:10.1016/j.ijpharm.2009.01.02319429296
   PubMedGoogle Scholar
• Zhang Q, Lu Y, Xu X, et al. MR molecular imaging of HCC employing a regulated ferritin gene carried by a modified polycation vector. Int J Nanomed. 2019;14:3189–3201. doi:10.2147/IJN.S191270
   PubMed Web of Science ®Google Scholar
• Cheng S, Mi R, Xu Y, et al. Ferritin heavy chain as a molecular imaging reporter gene in glioma xenografts. J Cancer Res Clin Oncol. 2017;143(6):941–951. doi:10.1007/s00432-017-2356-z28247036
   PubMed Web of Science ®Google Scholar
• Aung W, Hasegawa S, Koshikawa-Yano M, et al. Visualization of in vivo electroporation-mediated transgene expression in experimental tumors by optical and magnetic resonance imaging. Gene Ther. 2009;16(7):830–839. doi:10.1038/gt.2009.5519458649
   PubMed Web of Science ®Google Scholar
• Feng Y, Liu Q, Zhu J, et al. Efficiency of ferritin as an MRI reporter gene in NPC cells is enhanced by iron supplementation. J Biomed Biotechnol. 2012. 2012:434878.doi:10.1155/2012/434878
   Google Scholar
• Pereira SM, Moss D, Williams SR, et al. Overexpression of the MRI reporter genes ferritin and transferrin receptor affect iron homeostasis and produce limited contrast in mesenchymal stem cells. Int J Mol Sci. 2015;16(7):15481–15496. doi:10.3390/ijms16071548126184159
   PubMed Web of Science ®Google Scholar
• Pereira SM, Herrmann A, Moss D, et al. Evaluating the effectiveness of transferrin receptor-1 (TfR1) as a magnetic resonance reporter gene. Contrast Media Mol Imaging. 2016;11(3):236–244. doi:10.1002/cmmi.168626929139
   PubMed Web of Science ®Google Scholar
• Luo M, Lewik G, Ratcliffe JC, et al. Systematic evaluation of transferrin-modified porous silicon nanoparticles for targeted delivery of doxorubicin to glioblastoma. ACS Appl Mater Interfaces. 2019;11(37):33637–33649. doi:10.1021/acsami.9b1078731433156
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Pattni B, et al. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release. 2018;277:89–101. doi:10.1016/j.jconrel.2018.03.00629522834
   PubMed Web of Science ®Google Scholar